Abstract: The present disclosure is directed to a method for cultivating a Bordetella species, comprising: cultivating a Bordetella species under aerobic conditions in a liquid culture medium; and maintaining a pH of the liquid culture medium by using a strong acid, such as nitric acid, or using a first and second acid, wherein the first acid is an inorganic acid that dissociates essentially completely in water, such as nitric acid, hydrochloric acid or sulfuric acid, and wherein the second acid is an inorganic acid having an acid dissociation constant (pKa) of greater than 1, such as phosphoric acid. Methods for increasing the yield of Bordetella fimbrial agglutinogen 2 and fimbrial agglutinogen 3 (FIM2/3) in a supernatant fraction from a Bordetella culture are also provided.
Type:
Grant
Filed:
March 19, 2019
Date of Patent:
April 30, 2024
Assignee:
SANOFI PASTEUR INC.
Inventors:
Patrick Farrell, Bo Zhi Sun, Fabien Barbirato, Javier de Jesus Menendez Diaz, Andrew Chiappetta
Abstract: Methods and uses of compositions (e.g. comprising one or more microbial strains, one or more components, one or more metabolites, or a combination thereof) for treating neurodegenerative diseases, disorders, and conditions are disclosed.
Abstract: The present invention relates to a nucleic acid molecule encoding a chain myeloid capable of specifically binding to CD33, CD16 and CD123, wherein said nucleic molecule comprises: (a) a nucleic add molecule encoding a protein represented by SEQ ID NO:1; (b) a nucleic acid molecule represented by SEQ ID NO:2; (c) the nucleic add molecule of (b), wherein each thymine is replaced by urea; (d) a nucleic acid molecule encoding a protein having at least 98% sequence identity to the protein of (a); or (e) a nucleic add molecule that is degenerate with respect to the nucleic acid molecule of (b) or (c). The present invention further relates to a vector comprising the nucleic acid molecule of the invention, a host cell transformed or transfected with the nucleic acid molecule or the vector of the invention, as well as to a method for the production of a single chain myeloid capable of specifically binding to CD33, CD16 and CD123.
Abstract: The present invention relates to methods for the in vitro diagnosis of lung cancer in a subject, comprising the detection of progastrin using at least one progastrin-binding antibody. According to the method of the invention, the subject is diagnosed with a lung cancer when progastrin is detected in the sample.
Abstract: Polypeptides comprising a fragment of a teleost invariant chain fused to one or more antigens can enhance T cell response. Alternatively a teleost invariant chain fused to one or more antigens or antigenic fragments thereof can be used. A polynucleotide encoding such polypeptides, vectors comprising such polynucleotides, collection of vectors comprising such polynucleotides are also disclosed. The use of such polypeptides, polynucleotides, vectors for treating or preventing diseases, in particular tumor diseases are also encompassed by the present invention. The teleost invariant chain polypeptides or fragments thereof act as “T cell enhancer” converting non-immunogenic antigenic sequences into immunogenic T cell antigens.
Abstract: The present invention relates to a coding gene of the SOSEKI protein SOK2 and an application thereof, wherein through molecular regulation of the SOSEKI protein SOK2, the flowering time of Panicum virgatum is delayed, biomass is increased, lignin content in the cell wall of Panicum virgatum is reduced and the fermentable sugar yield is boosted.
Abstract: The application discloses method of immunising against Neisseria meningitidis infection comprising the steps of a) immunising a human patient at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least one, two or three bacterial saccharide(s) separately conjugated to a carrier protein to form at least one, two or three bacterial saccharide conjugate(s); and b) immunising the human patient at a second age of between 12 and 24 months with a Neisseria meningitidis conjugate vaccine comprising at least two capsular saccharides selected from the group consisting of N. meningitidis serogroup A capsular saccharide (MenA), N. meningitidis serogroup C capsular saccharide (MenC), N. meningitidis serogroup W135 capsular saccharide (MenW135), and N.
Abstract: Disclosed herein are compositions and methods for treating uterine fibroids in vivo, and methods of reducing symptoms associated with uterine fibroids, including pain, bleeding and infertility. The disclosed compositions comprise collagenase in an amount effective to cause shrinkage and/or reduce stiffness of uterine fibroids.
Type:
Grant
Filed:
October 14, 2020
Date of Patent:
January 16, 2024
Assignees:
The Johns Hopkins University, Duke University, BioSpecifics Technologies LLC
Inventors:
James H. Segars, Phyllis Carolyn Leppert, Thomas L. Wegman, Jean-Marie Soma
Abstract: An isolated Streptococcus pneumoniae membrane vesicle microparticle (MP), wherein said MP comprises: the protein Ply at the level of ?0.070 ?g/?g total protein in the MP; and/or the protein LytA at the level of ?0.070 ?g/?g total protein in the MP; and/or the protein PspC at the level of ?0.130 ?g/?g total protein in the MP; and/or the protein RrgB at the level of ?0.020 ?g/?g total protein in the MP. Compositions comprising such MPs. Uses thereof in particular in immunization, as well as methods of manufacture thereof.
Type:
Grant
Filed:
December 21, 2017
Date of Patent:
December 19, 2023
Assignee:
ZalVac AB
Inventors:
Birgitta Henriques Normark, Mario Codemo, Federico Iovino, Sandra Muschiol, Staffan Normark, Sun Nyunt Wai
Abstract: The present disclosure provides a subunit vaccine of contagious caprine pleuropneumonia and preparation method and use thereof, belonging to the technical field of preparation of animal infectious disease vaccine. The combination of Mycoplasma capricolum subsp. capripneumoniae immunoproteins comprises Mycoplasma capricolum subsp. capripneumoniae immunoproteins A, B, C, D and E; the mass ratio of Mycoplasma capricolum subsp. capripneumoniae immunoproteins A, B, C, D and E is (0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5):(0.5-1.5). The subunit vaccine of contagious caprine pleuropneumonia comprises the combination of Mycoplasma capricolum subsp. capripneumoniae immunoproteins and adjuvant; the subunit vaccine has the advantages of high safety, good immunization effect, high stability and minor adverse effects.
Type:
Grant
Filed:
June 1, 2021
Date of Patent:
October 31, 2023
Assignee:
Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences
Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the first exon of the human T cell receptor (TCR) alpha constant region gene. The engineered meganucleases can exhibit at least one optimized characteristic, such as enhanced (i.e., increased) specificity or efficiency of cleavage, when compared to the first-generation meganuclease TRC 1-2x.87EE. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating diseases, such as cancer.
Type:
Grant
Filed:
April 11, 2019
Date of Patent:
October 17, 2023
Assignee:
Precision BioSciences, Inc.
Inventors:
James Jefferson Smith, Janel Lape, Hui Li, Jochen Genschel
Abstract: The invention, in some aspects, relates to the preparation and use of signaling reporter islands (SiRIs) in single cells. Compositions of the invention that produce SiRIs can be delivered to a cell resulting in the presence of one or more SiRIs in the cell. Methods of the invention include detecting signals generated by elements in the SiRIs in a cell and use of the detected signals to determine and analyze simultaneous physiological processes within the cell, or cells.
Type:
Grant
Filed:
September 14, 2020
Date of Patent:
October 10, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Changyang Linghu, Shannon L. Johnson, Edward Stuart Boyden
Abstract: A method for transfecting microorganisms comprises inoculating a growth media consisting of at least one of sterile LB media and tryptic soy broth with microorganism cells (cells) consisting of at least one of E.coli (DH5?), C. lytica, or B. subtilus, Pichia pastoris; growing the cells at between 28-40° C. to achieve a desired cell density; harvesting the cells; adding a protein ionic liquid consisting of at least one of green fluorescent protein (GFP), ferritin, rabbit IgG antibodies, and photosystem II from spinach ionic liquid to the cells; suspending the cells in the protein ionic liquid; freezing the suspended cells between ?20 to ?212° C.; and removing at least 99% of water from the frozen suspended cells to make a cell powder. The cell powder may be reconstituted in Tris HCl buffer and mixed to obtain uniform cell suspension; and centrifuged to obtain cell pellet.
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
October 10, 2023
Assignee:
United States of America as represented by the Secretary of the Air Force
Inventors:
Joseph M Slocik, Rajesh R. Naik, Patrick B Dennis
Abstract: The present disclosure relates to proteins comprising a target-binding domain for detection of a target of interest, methods, compositions and kits thereof.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
August 29, 2023
Assignee:
Massachusetts Institute of Technology
Inventors:
Hadley Sikes Johnson, Eric Alexander Miller, Ki-Joo Sung
Abstract: A modified bacteriophage capable of infecting a plurality of different target bacteria, which bacteriophage includes a toxin gene encoding a toxin protein which is toxic to the target bacteria; wherein the bacteriophage is lytic; and wherein the bacteriophage expresses host range determinant proteins which have a plurality of bacterial host specificities.
Abstract: The application relates to methods based on modulating mammalian intestinal and/or pancreatic microbiota and related probiotic, prebiotic, and anti-bacterial compositions. Specifically, the application relates to the use of microbiome for prevention, treatment and diagnosis of pancreatic cancers or tumors, such as pancreatic ductal adenocarcinoma.
Type:
Grant
Filed:
February 6, 2018
Date of Patent:
August 15, 2023
Assignee:
NEW YORK UNIVERSITY
Inventors:
George Miller, Deepak Saxena, Smruti Pushalkar
Abstract: Provided are a live recombinant Mycobacterium bovis-BCG strain and a tuberculosis (TB) vaccine or immunogenic composition comprising a nucleic acid capable of overexpression, the nucleic acid encoding PhoP and PhoR proteins. A method for treatment or prophylaxis of a mammal against challenge by Mycobacterium tuberculosis or Mycobacterium bovis using the strain is also provided.
Abstract: Disclosed is a method for measuring a biomarker in a biological sample of the IPAF patient, wherein the biomarker comprises at least one selected from the group consisting of CXCL9 and CXCL10, and a measurement result of the biomarker is used as an index for determining treatment responsiveness to anti-inflammatory therapy.
Type:
Grant
Filed:
April 14, 2020
Date of Patent:
August 8, 2023
Assignees:
SAPPORO MEDICAL UNIVERSITY, SYSMEX CORPORATION